Dyne Therapeutics Files 8-K: Material Agreement & Other Events
Ticker: DYN · Form: 8-K · Filed: May 22, 2024 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $31.00, $29.14, $305.4 m, $351.4 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, financials
TL;DR
Dyne Therapeutics signed a big deal, filed financials. Details TBD.
AI Summary
On May 21, 2024, Dyne Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The filing does not specify the nature of the agreement or the financial details.
Why It Matters
This 8-K filing indicates a significant event for Dyne Therapeutics, potentially involving a new partnership, acquisition, or financing, which could impact its future operations and stock performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative depending on the specifics not yet disclosed.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Registrant
- May 21, 2024 (date) — Date of earliest event reported
- 1560 Trapelo Road, Waltham, Massachusetts 02451 (address) — Principal Executive Offices
- (781) 786-8230 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Dyne Therapeutics?
The filing does not specify the nature of the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 21, 2024.
What is the principal executive office address for Dyne Therapeutics?
The principal executive office is located at 1560 Trapelo Road, Waltham, Massachusetts 02451.
What is the SEC file number for Dyne Therapeutics?
The SEC file number is 001-39509.
What items are covered in this 8-K filing?
This 8-K filing covers entry into a material definitive agreement, other events, and financial statements and exhibits.
Filing Stats: 1,461 words · 6 min read · ~5 pages · Grade level 13.7 · Accepted 2024-05-22 07:59:02
Key Financial Figures
- $0.0001 — ange on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
- $31.00 — ing price of the Underwritten Shares is $31.00 per share, and the Underwriters have ag
- $29.14 — he Underwriting Agreement at a price of $29.14 per share. Under the terms of the Under
- $305.4 m — from the Offering will be approximately $305.4 million, or approximately $351.4 million
- $351.4 million — mately $305.4 million, or approximately $351.4 million if the Underwriters exercise in full th
Filing Documents
- d812513d8k.htm (8-K) — 32KB
- d812513dex11.htm (EX-1.1) — 218KB
- d812513dex51.htm (EX-5.1) — 10KB
- d812513dex991.htm (EX-99.1) — 9KB
- g812513g0522055857445.jpg (GRAPHIC) — 2KB
- g812513g0522060047594.jpg (GRAPHIC) — 7KB
- g812513g0522062611349.jpg (GRAPHIC) — 3KB
- g812513g0522062611541.jpg (GRAPHIC) — 1KB
- 0001193125-24-144470.txt ( ) — 475KB
- dyn-20240521.xsd (EX-101.SCH) — 3KB
- dyn-20240521_lab.xml (EX-101.LAB) — 18KB
- dyn-20240521_pre.xml (EX-101.PRE) — 11KB
- d812513d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: May 22, 2024 By: /s/ John G. Cox Name: John G. Cox Title: President and Chief Executive Officer